NCT04045730 is a Phase 2 clinical trial of Gemcitabine in Pancreas Adenocarcinoma, sponsored by Yale University.

Who is sponsoring NCT04045730?

NCT04045730 is sponsored by Yale University.

What drugs are being tested in NCT04045730?

Interventions in NCT04045730: Gemcitabine.

What condition does NCT04045730 study?

NCT04045730 studies Pancreas Adenocarcinoma.

Is NCT04045730 still recruiting?

NCT04045730 is currently withdrawn. Last updated 9 January 2020.

Last reviewed 2020-01-09 · How we verify

NCT04045730

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.

Withdrawn Phase 2 Last updated 9 January 2020

What this trial tests

Phase 2 trial testing Gemcitabine in Pancreas Adenocarcinoma. Withdrawn.

Timeline

15 November 2019

Primary endpoint
31 December 2019

31 July 2021

Quick facts

Lead sponsor	Yale University
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	15 November 2019
Primary completion	31 December 2019
Estimated completion	31 July 2021

Drugs / interventions tested

Gemcitabine (gemcitabine) — full drug profile →

Conditions studied

Pancreas Adenocarcinoma — all drugs for Pancreas Adenocarcinoma →

Sponsor

Yale University

Who can join

18 and older, any sex, with Pancreas Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label single arm phase 2 study for patients with metastatic pancreatic ductal adenocarcinoma who have not received any prior systemic therapies.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer.
Ostios-Garcia L, Villamayor J, Garcia-Lorenzo E, Vinal D, et al · · 2021 · cited 22× · PMID 34790007 · DOI 10.3748/wjg.v27.i40.6775
Boosting antitumor efficacy of nanoparticles by modulating tumor mechanical microenvironment.
Zhang X, Zhang X, Yong T, Gan L, et al · · 2024 · cited 11× · PMID 38876044 · DOI 10.1016/j.ebiom.2024.105200
Challenges and Opportunities in Targeting the Complex Pancreatic Tumor Microenvironment.
Finan JM, Guo Y, Goodyear SM, Brody JR. · · 2024 · cited 9× · PMID 39735733 · DOI 10.1200/oa-24-00050
Patient-Derived Ex Vivo Cultures and Endpoint Assays with Surrogate Biomarkers in Functional Testing for Prediction of Therapeutic Response.
Tsukamoto Y, Hirashita Y, Shibata T, Fumoto S, et al · · 2023 · cited 3× · PMID 37627132 · DOI 10.3390/cancers15164104

Verify or expand the search:

Other trials of Gemcitabine

Trials testing the same drug.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and · Phase 2 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting

Other recruiting trials for Pancreas Adenocarcinoma

Currently open trials in the same condition.

NCT07043270 — 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC · Phase 2 · recruiting
NCT07262957 — Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Inc · Phase 4 · recruiting
NCT07081360 — Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer · Phase 3 · recruiting
NCT07022015 — Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy · NA · recruiting
NCT06497777 — The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04045730 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 9 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04045730.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing